Graft Versus Host Disease (GVHD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Graft Versus Host Disease (GVHD) Clinical Trial Market Report Overview
Graft versus host disease (GVHD) clinical trial market research report provides top line data relating to the clinical trials on Graft Versus Host Disease (GVHD). The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials.
Key Regions | · North America
· Europe · Asia-Pacific · Middle East and Africa · South and Central America |
Key Countries | · The United States
· China · Italy · Japan · Germany |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · Sanofi Pfizer Inc
· Incyte Corp · Novartis AG · F. Hoffmann-La Roche Ltd · Johnson & Johnson |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Graft Versus Host Disease (GVHD) Clinical Trials Segmentation by Regions and Countries
North America led the GVHD clinical trials landscape with a significant number of the clinical trials conducted as of March 2024.
The key regions considered for GVHD clinical trials analysis are Asia-Pacific, Europe, North America, Middle East and Africa, and South and Central America.
In the country-wise analysis, the US had the highest number of GVHD clinical trials, as of March 2024. France had the highest average patient enrollment in GVHD clinical trials, during the same time.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the US had the highest proportion of Graft Versus Host Disease (GVHD) to Immunology clinical trials as of March 2024.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey had the highest proportion of Graft Versus Host Disease (GVHD) to Immunology clinical trials as of March 2024.
GVHD Clinical Trials Analysis by Regions, 2024 (%)
Buy the Full Report for More Regional Insights into the GVHD Clinical Trials Download a Free Report Sample
Graft Versus Host Disease (GVHD) Clinical Trials Segmentation by Sponsor Types
The key sponsor types for GVHD clinical trials are company, institution, and the government. As of March 2024, a significant percentage of GVHD clinical trials conducted were sponsored by institution sponsor type.
GVHD Clinical Trials Analysis by Sponsor Type, 2024 (%)
Buy the Full Report for More Insights into the GVHD Clinical Trials Sponsor Types Download a Free Report Sample
Graft Versus Host Disease (GVHD) Clinical Trials - Competitive Landscape
Sanofi conducted the highest number of GVHD clinical trials as of March 2024.
A few of the prominent sponsors in the GVHD clinical trials market are:
- Sanofi
- Incyte Corp
- Novartis AG
- Hoffmann-La Roche Ltd
- Johnson & Johnson
GVHD Clinical Trials Analysis by Sponsors, 2024 (%)
Buy the Full Report to Know More About the Leading Sponsors of GVHD Clinical Trials
Segments Covered in the Report
Graft Versus Host Disease (GVHD) Clinical Trials Regional Outlook (2024)
- Asia-Pacific
- Europe
- North America
- Middle East and Africa
- South and Central America
Graft Versus Host Disease (GVHD) Clinical Trials Country Outlook (2024)
- The United States
- China
- Italy
- Japan
- Germany
Graft Versus Host Disease (GVHD) Clinical Trials Sponsor Type Outlook (2024)
- Company
- Institution
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment.
- The report provides enrollment trends for the past five years.
- The report provides latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional and country level.
Incyte Corp
Novartis AG
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Pfizer Inc
Takeda Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Bellicum Pharmaceuticals Inc
Amgen Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of GVHD clinical trials in March 2024?
North America accounted for the highest number of GVHD clinical trials as of March 2024.
-
Which country conducted the highest number of GVHD clinical trials in March 2024?
The US conducted the highest number of GVHD clinical trials as of March 2024.
-
Which sponsor type was the most prominent in the GVHD clinical trials in March 2024?
As of March 2024, most of the GVHD clinical trials conducted were sponsored by institution sponsor type.
-
Who are the leading sponsors of GVHD clinical trials?
A few of the leading sponsors of GVHD clinical trials are Sanofi, Incyte Corp, Novartis AG, F. Hoffmann-La Roche Ltd, and Johnson & Johnson among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.